Q. Zhang
Merck & Co.
8 Papers
80 Citations
Q. Zhang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Asthma & Montelukast. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Asthma-Related Health Care Resource Use Among Asthmatic Children With and Without Concomitant Allergic Rhinitis
TL;DR: A unified treatment strategy for asthma and allergic rhinitis, as recommended by the Allergic Rhinitis and Its Impact on Asthma initiative, might reduce the costs of treating these conditions.
162
Asthma-related resource use and cost by GINA classification of severity in three European countries.
TL;DR: Inadequate control of asthma symptoms among patients with severe persistent asthma could not be entirely explained by under-prescribing of asthma medications, and the use of inhaled corticosteroids by patients with intermittent asthma might reflect misclassification of asthma severity.
58
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.
T. M. Tessa Marthe Kole,Elise Vanden Berghe,Monica Kraft,Judith M. Vonk,Martijn C. Nawijn,Salman Siddiqui,Kai Sun,Leonardo M. Fabbri,Klaus F. Rabe,Gabriele Nicolini,Christopher E. Brightling,Dave Singh,T. van der Molen,Sven-Erik Dahlén,Alvar Agusti,Rosa Faner,Jadwiga A. Wedzicha,Gavin C. Donaldson,Huib A. M. Kerstjens,Philipp Badorrek,Mariëlle E.A.C. Broeders,Wim Boersma,Alfredo Chetta,Alberto Cukier,Mike D'Amato,Ratko Djukanovic,Maria Pia Foschino,C. Gessner,Nicola A. Hanania,Raul Martin,Stefano Milleri,Ron Olivenstein,Pierluigi Paggiaro,Emilio Pizzichini,Vicente Plaza Moral,D. S. Postma,Nicola Scichilone,Robert Schilz,Antonio Spanevello,Rafael Stelmach,J. Sebastiaan Vroegop,O. Usmani,Q. Zhang,H. Ahmed,David B. Allen,Séverine Ballereau,Manohara Batuwitage,A. Bedding,Annelie F. Behndig,Anna Berglind,André Berton,Jeannette Bigler,Michael Boedigheimer,Klaus Bønnelykke,Paul Brinkman,Andrew Bush,Davide Campagna,Carmen Casaulta,Amphun Chaiboonchoe,Trevor Davison,Bertrand De Meulder,Ingrid Delin,Patrick Dennison,Paul Dodson,L. El Hadjam,D. Erzen,C. Faulenbach,K. Fichtner,Neil Fitch,Elena Formaggio,Martina Gahlemann,Gabriella Gálffy,D. Garissi,T. Garret,E. Guillmant-Farry,Elisabeth Henriksson,Uruj Hoda,JM Hohlfeld,X. Hu,Anna James,Kjetil Breivik Johnson,Nathalie Jullian,Gina Kerry,Matthias Klüglich,Richard G. Knowles,Jon R Konradsen,Kosmas Kretsos,L. Krueger,Ann-Sofie Lantz,Christopher Larminie,Philipp Latzin,Diane Lefaudeux,Nicolas Lemonnier,Lindsay A Lowe,René Lutter,Adina Manta,Alexander Mazein,L. McEvoy,Andrew Menzies-Gow,Nadia Mores,Catherine S. Murray,K Nething,Ulf Nihlén,R M Niven,Bjoern Nordlund,Saul Hannington Nsubuga,Johann Pellet,Carlos Pisón,G. Praticò,M. Puig Valls,Klaus Riemann,J.P. Rocha,Christos Rossios,Giuseppe Santini,Mária Sági,S Scott,Nitin Sehgal,A. Selby,P. O. Söderman,A.O. Sogbesan,Franziska Spycher,Schroder Stephan,Jakob Stokholm,Meera Sunther,Marton Szentkereszty,Lilla Tamási,Kamran Tariq,S. Valente,W.M.C. van Aalderen,C. M. van Drunen,Jonathan van Eyll,Akshay Vyas,W. Zetterguist,Z Zolkipli,Aeilko H. Zwinderman,Alexandre Escolà Agustí,J. Wedzicha,Robab Breyer-Kohansal,Anke-Hilse Maitland-van der Zee,Erik Melén,James P. Allinson,Lowie E.G.W. Vanfleteren,J Vestbo,Ian M. Adcock,Lies Lahousse,Maarten van den Berge,Paul Alter,F. Barbé,Marie-Kathrin Breyer,Otto C. Burghuber,Miquel Teixido Casas,Kian Fan Chung,Borja G. Cosío,Fatima Crispi,Jordi de Batlle,J. Fitting,J. Garcia,Jenny Hallberg,Sylvia Hartl,Dave West Hartford Jarvis,A. Mathioudakis,L. Nicod,Alberto Papi,Ann Ritchie,Torben Sigsgaard,Peter J. Sterk,Anja Ullman,Kilian Vellvé,C. Vogelmeier,A. Wheelock,Craig E. Wheelock +170 more
TL;DR: In this article , a post-bronchodilator FEV1/forced vital capacity (FVC) of less than the lower limit of normal at recruitment was defined in a subset of patients with asthma.
Treatment and Outcomes in Patients with Asthma and Allergic Rhinitis in the United Kingdom
TL;DR: In asthma and allergic rhinitis, treatment with ICS+MON or hdICS was associated with lower rates of asthma control failure and fewer treatment changes than the ICS-LABA group, and MON users required fewer oral corticosteroids.
14
Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK.
TL;DR: Persistence with first-time ICS monotherapy is poor among children with persistent asthma, and adherence to asthma controller therapy decreases over time.
7